Logo image of JAZZ

JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Price, Quote, News and Overview

NASDAQ:JAZZ - Nasdaq - IE00B4Q5ZN47 - Common Stock - Currency: USD

117.18  +0.22 (+0.19%)

After market: 117.18 0 (0%)

JAZZ Quote, Performance and Key Statistics

JAZZ PHARMACEUTICALS PLC

NASDAQ:JAZZ (5/1/2025, 5:20:02 PM)

After market: 117.18 0 (0%)

117.18

+0.22 (+0.19%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High148.06
52 Week Low95.49
Market Cap7.12B
Shares60.73M
Float58.81M
Yearly DividendN/A
Dividend YieldN/A
PE5.53
Fwd PE4.93
Earnings (Next)05-06 2025-05-06/amc
IPO01-18 2012-01-18


JAZZ short term performance overview.The bars show the price performance of JAZZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 15

JAZZ long term performance overview.The bars show the price performance of JAZZ in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 5 -5 -10 -15 -20

The current stock price of JAZZ is 117.18 USD. In the past month the price decreased by -7.32%. In the past year, price increased by 6.52%.

JAZZ PHARMACEUTICALS PLC / JAZZ Daily stock chart

JAZZ Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 61.08 752.80B
JNJ JOHNSON & JOHNSON 15.37 372.23B
NVO NOVO-NORDISK A/S-SPONS ADR 18.96 291.20B
NVS NOVARTIS AG-SPONSORED ADR 13.21 219.89B
AZN ASTRAZENECA PLC-SPONS ADR 18.95 218.61B
MRK MERCK & CO. INC. 10.69 209.51B
PFE PFIZER INC 7.45 135.72B
SNY SANOFI-ADR 14.02 132.44B
BMY BRISTOL-MYERS SQUIBB CO 6.76 100.94B
GSK GSK PLC-SPON ADR 7.05 78.52B
ZTS ZOETIS INC 26.29 69.43B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.67 47.30B

About JAZZ

Company Profile

JAZZ logo image Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The firm is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Company Info

JAZZ PHARMACEUTICALS PLC

Fifth Floor, Waterloo Exchange, Waterloo Road

DUBLIN DUBLIN D04 IE

CEO: Bruce C. Cozadd

Employees: 2800

Company Website: https://www.jazzpharma.com/

Investor Relations: http://investor.jazzpharma.com

Phone: 35316347800

JAZZ PHARMACEUTICALS PLC / JAZZ FAQ

What is the stock price of JAZZ PHARMACEUTICALS PLC today?

The current stock price of JAZZ is 117.18 USD. The price increased by 0.19% in the last trading session.


What is the ticker symbol for JAZZ PHARMACEUTICALS PLC stock?

The exchange symbol of JAZZ PHARMACEUTICALS PLC is JAZZ and it is listed on the Nasdaq exchange.


On which exchange is JAZZ stock listed?

JAZZ stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JAZZ PHARMACEUTICALS PLC stock?

24 analysts have analysed JAZZ and the average price target is 192.71 USD. This implies a price increase of 64.46% is expected in the next year compared to the current price of 117.18. Check the JAZZ PHARMACEUTICALS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JAZZ PHARMACEUTICALS PLC worth?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a market capitalization of 7.12B USD. This makes JAZZ a Mid Cap stock.


How many employees does JAZZ PHARMACEUTICALS PLC have?

JAZZ PHARMACEUTICALS PLC (JAZZ) currently has 2800 employees.


What are the support and resistance levels for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

JAZZ PHARMACEUTICALS PLC (JAZZ) has a support level at 101.27 and a resistance level at 117.19. Check the full technical report for a detailed analysis of JAZZ support and resistance levels.


Is JAZZ PHARMACEUTICALS PLC (JAZZ) expected to grow?

The Revenue of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 6.18% in the next year. Check the estimates tab for more information on the JAZZ EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JAZZ PHARMACEUTICALS PLC (JAZZ) stock pay dividends?

JAZZ does not pay a dividend.


When does JAZZ PHARMACEUTICALS PLC (JAZZ) report earnings?

JAZZ PHARMACEUTICALS PLC (JAZZ) will report earnings on 2025-05-06, after the market close.


What is the Price/Earnings (PE) ratio of JAZZ PHARMACEUTICALS PLC (JAZZ)?

The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 5.53. This is based on the reported non-GAAP earnings per share of 21.19 and the current share price of 117.18 USD. Check the full fundamental report for a full analysis of the valuation metrics for JAZZ.


What is the Short Interest ratio of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?

The outstanding short interest for JAZZ PHARMACEUTICALS PLC (JAZZ) is 7.71% of its float. Check the ownership tab for more information on the JAZZ short interest.


JAZZ Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ turns out to be only a medium performer in the overall market: it outperformed 61.91% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

JAZZ Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to JAZZ. JAZZ has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

JAZZ Financial Highlights

Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 21.19. The EPS increased by 15.67% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.77%
ROA 4.66%
ROE 13.68%
Debt/Equity 1.49
Chartmill High Growth Momentum
EPS Q2Q%31.47%
Sales Q2Q%7.53%
EPS 1Y (TTM)15.67%
Revenue 1Y (TTM)6.12%

JAZZ Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to JAZZ. The Buy consensus is the average rating of analysts ratings from 24 analysts.

For the next year, analysts expect an EPS growth of 12.18% and a revenue growth 6.18% for JAZZ


Ownership
Inst Owners100.43%
Ins Owners2.39%
Short Float %7.71%
Short Ratio3.62
Analysts
Analysts83.33
Price Target192.71 (64.46%)
EPS Next Y12.18%
Revenue Next Year6.18%